ReviewFrontiers in medicine2021
Potential Associations Between Microbiome and COVID-19.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Diagnostic, Prognostic, and Therapeutic Roles of Gut Microbiota in COVID-19: A Comprehensive Systematic Review.Frontiers in cellular and infection microbiology · 2022Pooled it
- Assessment of the bacterial community of the human upper respiratory tract in patients affected by Covid-19.Genetics and molecular biology · 2026Article
- A perfect storm: the immunological and pathophysiological landscape of pediatric post-COVID-19 condition.Frontiers in immunology · 2026Review
- Gut Microbiota and COVID-19: Unraveling the Gut-Lung Axis and Immunomodulatory Therapies.ACS infectious diseases · 2025Review
- The dynamic linkage between covid-19 and nutrition: a review from a probiotics perspective using machine learning and bibliometric analysis.Frontiers in nutrition · 2025Article
- Impact of the COVID-19 Pandemic on Microbial Profiles and Clinical Outcomes in Orbital and Preseptal Cellulitis.Microorganisms · 2024Article
- Bibliometric analysis of intestinal microbiota and lung diseases.Frontiers in cellular and infection microbiology · 2024Article
- Mitochondria in COVID-19: from cellular and molecular perspective.Frontiers in physiology · 2024Review
- Baseline Gut Microbiome Signatures Correlate with Immunogenicity of SARS-CoV-2 mRNA Vaccines.International journal of molecular sciences · 2023Article
- Serum biomarkers for nutritional status as predictors in COVID-19 patients before and after vaccination.Journal of functional foods · 2023Article
- Persistent SARS-CoV-2 Infection, EBV, HHV-6 and Other Factors May Contribute to Inflammation and Autoimmunity in Long COVID.Viruses · 2023Review
- Review
- COVID-19 and brain-heart-lung microbial fingerprints in Italian cadavers.Frontiers in molecular biosciences · 2023Article
- The triangle relationship between human genome, gut microbiome, and COVID-19: opening of a Pandora's box.Frontiers in microbiology · 2023Review
- Gastrointestinal microbiota: A predictor of COVID-19 severity?World journal of gastroenterology · 2022Review
- Oral intake of Kluyveromyces marxianus B0399 plus Lactobacillus rhamnosus CECT 30579 to mitigate symptoms in COVID-19 patients: A randomized open label clinical trial.Medicine in microecology · 2022Article
- SARS-CoV-2-associated gut microbiome alteration; A new contributor to colorectal cancer pathogenesis.Pathology, research and practice · 2022Review
- COVID-19 and the Human Gut Microbiome: An Under-Recognized Association.Chonnam medical journal · 2022Review
- Review
- The Role of Exposomes in the Pathophysiology of Autoimmune Diseases II: Pathogens.Pathophysiology : the official journal of the International Society for Pathophysiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has plunged the world into a major crisis. The disease is characterized by strong infectivity, high morbidity, and high mortality. It is still spreading in some countries. Microbiota and their metabolites affect human physiological health and diseases by participating in host digestion and nutrition, promoting metabolic function, and regulating the immune system. Studies have shown that human microecology is associated with many diseases, including COVID-19. In this research, we first reviewed the microbial characteristics of COVID-19 from the aspects of gut microbiome, lung microbime, and oral microbiome. We found that significant changes take place in both the gut microbiome and airway microbiome in patients with COVID-19 and are characterized by an increase in conditional pathogenic bacteria and a decrease in beneficial bacteria. Then, we summarized the possible microecological mechanisms involved in the progression of COVID-19. Intestinal microecological disorders in individuals may be involved in the occurrence and development of COVID-19 in the host through interaction with ACE2, mitochondria, and the lung-gut axis. In addition, fecal bacteria transplantation (FMT), prebiotics, and probiotics may play a positive role in the treatment of COVID-19 and reduce the fatal consequences of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.